Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Sardu, Celestino ^a   Barbieri, Michelangela ^a   Rizzo, Maria Rosaria ^a   Paolisso, Pasquale ^a   Paolisso, Giuseppe ^a   Marfella, Raffaele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DICER; EXPORTIN 5; MICRORNA; MICRORNA 145; MICRORNA 145 5P; MICRORNA 26B 5P; MICRORNA 29; MICRORNA 29A 3P; MICRORNA 30; MICRORNA 30E 5P; MICRORNA 92A 3P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR EFFECT; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DEFIBRILLATOR; DIABETIC PATIENT; EXCITATION CONTRACTION COUPLING; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; ION CURRENT; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; COMPLICATION; GENETICS; HEART FAILURE; METABOLISM; TREATMENT OUTCOME;

CARDIAC RESYNCHRONIZATION THERAPY; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; MICRORNAS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84948448156     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/7292564     Document Type: Review

References (58)

1. D. T. Eurich, D. L. Weir, S. R. Majumdar et al., "Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients," Circulation: Heart Failure, vol. 6, no. 3, pp. 395-402, 2013.
2. G. Santulli, "Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts," Journal of Cardiovascular Disease, vol. 1, no. 1, pp. 1-2, 2013.
3. E. S. Huang, N. Laiteerapong, J.Y. Liu, P.M. John, H.H. Moffet, and A. J. Karter, "Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study," JAMA Internal Medicine, vol. 174, no. 2, pp. 251-258, 2014.
4. L. R. Peterson, C. R. McKenzie, and J. E. Schaffer, "Diabetic cardiovascular disease: getting to the heart of the matter," Journal of Cardiovascular Translational Research, vol. 5, no. 4, pp. 436-445, 2012.
5. R. M. Cubbon, B. Adams, A. Rajwani et al., "Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischemic and non ischemic etiology," Diabetes & Vascular Disease Research, vol. 10, no. 4, pp. 330-336, 2013.
6. S. Nodari, A. Manerba, A. Vaccari et al., "Six-year prognosis of diabetic patients with coronary artery disease," European Journal of Clinical Investigation, vol. 42, no. 4, pp. 376-383, 2012.
7. A. J. Moss, W. J. Hall, D. S. Cannom et al., "Cardiac-resynchronization therapy for the prevention of heart-failure events," The New England Journal of Medicine, vol. 361, no. 14, pp. 1329-1338, 2009.
8. P. N. Peterson, M. A. Greiner, L. G. Qualls et al., "QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy," The Journal of the American Medical Association, vol. 310, no. 6, pp. 617-626, 2013.
9. M. Vanderheyden, W. Mullens, L. Delrue et al., "Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy. Responders versus non responders," Journal of the American College of Cardiology, vol. 51, no. 2, pp. 129-136, 2008.
10. M. R. Gold, C. Daubert, W. T. Abraham et al., "The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study," Heart Rhythm, vol. 12, no. 3, pp. 524-530, 2015.
11. D. T. Martin, S. McNitt, R. W. Nesto, M. K. Rutter, and A. J. Moss, "Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT)," Circulation: Heart Failure, vol. 4, no. 3, pp. 332-338, 2011.
12. J. G. F. Cleland, J.-C. Daubert, E. Erdmann et al., "The effect of cardiac resynchronization on morbidity and mortality in heart failure," The New England Journal of Medicine, vol. 352, no. 15, pp. 1539-1549, 2005.
13. G. B. Bleeker, M. J. Schalij, S. G. Molhoek et al., "Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus ≥70 years of age," The American Journal of Cardiology, vol. 96, no. 3, pp. 420-422, 2005.
14. G. Pulignano, D. Del Sindaco, L. Tavazzi et al., "Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF registry)," The American Heart Journal, vol. 143, no. 1, pp. 45-55, 2002.
15. S. Fumagalli, S. Valsecchi, G. Boriani et al., "Comparison of the usefulness of cardiac resynchronization therapy in three agegroups (<65, 65-74 and ≥75 Years) (from the InSync/InSync ICD Italian Registry)," The American Journal of Cardiology, vol. 107, no. 10, pp. 1510-1516, 2011.
16. P. W. X. Foley, S. Chalil, K. Khadjooi, R. E. A. Smith, M. P. Frenneaux, and F. Leyva, "Long-term effects of cardiac resynchronization therapy in octogenarians: a comparative study with a younger population," Europace, vol. 10, no. 11, pp. 1302-1307, 2008.
17. R. Cutro, M. W. Rich, and P. J. Hauptman, "Device therapy in patients with heart failure and advanced age: too much too late?" International Journal of Cardiology, vol. 155, no. 1, pp. 52-55, 2012.
18. D. B. Kramer, M. R. Reynolds, and S. L. Mitchell, "Resynchronization: considering device-based cardiac therapy in older adults," Journal of the American Geriatrics Society, vol. 61, no. 4, pp. 615-621, 2013.
19. C. Fantoni, F. Regoli, A. Ghanem et al., "Long-termoutcome in diabetic heart failure patients treated with cardiac resynchronization therapy," European Journal of Heart Failure, vol. 10, no. 3, pp. 298-307, 2008.
20. J. George, A. Barsheshet, A. J. Moss et al., "Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy," Annals of Noninvasive Electrocardiology, vol. 17, no. 1, pp. 14-21, 2012.
21. U.C. Hoppe, N. Freemantle, J. G. F. Cleland, M. Marijianowski, and E. Erdmann, "Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure," Diabetes Care, vol. 30, no. 3, pp. 722-724, 2007.
22. M. Mangiavacchi, M. Gasparini, S. Genovese et al., "Insulintreated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy," Pacing and Clinical Electrophysiology, vol. 31, no. 11, pp. 1425-1432, 2008.
23. A.C. Ruwald, C. Schuger, A. J. Moss et al., "Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT)," Circulation: Arrhythmia and Electrophysiology, vol. 7, no. 5, pp. 785-792, 2014.
24. C. Sardu, R. Marfella, and G. Santulli, "Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people," Journal of Cardiovascular Translational Research, vol. 7, no. 3, pp. 362-368, 2014.
25. R. Marfella, C. Di Filippo, N. Potenza et al., "Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders," European Journal of Heart Failure, vol. 15, no. 11, pp. 1277-1288, 2013.
26. C. Sardu, R. Marfella, G. Santulli, and G. Paolisso, "Functional role of miRNA in cardiac resynchronization therapy," Pharmacogenomics, vol. 15, no. 8, pp. 1159-1168, 2014.
27. X. Luo, Z. Pan, H. Shan et al., "MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation," The Journal of Clinical Investigation, vol. 123, no. 5, pp. 1939-1951, 2013.
28. E. van Rooij, L. B. Sutherland, J. E. Thatcher et al., "Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13027-13032, 2008.
29. Y. Shen, Z. Shen, L. Miao et al., "miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression," Antioxidants & Redox Signaling, vol. 22, no. 3, pp. 224-240, 2015.
30. Z. Chen, L. Wen, M. Martin et al., "Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of MicroRNA-92a," Circulation, vol. 131, no. 9, pp. 805-814, 2015.
31. X. Liu, Y. Cheng, J. Yang et al., "Flank sequences of miR-145/143 and their aberrant expression in vascular disease: mechanism and therapeutic application," Journal of the American Heart Association, vol. 2, no. 6, Article ID e000407, 2013.
32. G. Ruvkun and J. Giusto, "The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch," Nature, vol. 338, no. 6213, pp. 313-319, 1989.
33. V. Ambros, B. Bartel, D. P. Bartel et al., "A uniform system for microRNA annotation," RNA, vol. 9, no. 3, pp. 277-279, 2003.
34. D. P. Bartel and C.-Z. Chen, "Micromanagers of gene expression: the potentially widespread influence ofmetazoan microRNAs," Nature Reviews Genetics, vol. 5, no. 5, pp. 396-400, 2004.
35. V. N. Kim, "MicroRNA biogenesis: coordinated cropping and dicing," Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376-385, 2005.
36. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281-297, 2004.
37. E. Lund, S. Güttinger, A. Calado, J. E. Dahlberg, and U. Kutay, "Nuclear export of microRNA precursors," Science, vol. 303, no. 5654, pp. 95-98, 2004.
38. A. M. Denli, B. B. J. Tops, R. H. A. Plasterk, R. F. Ketting, and G. J. Hannon, "Processing of primary microRNAs by the Microprocessor complex," Nature, vol. 432, no. 7014, pp. 231-235, 2004.
39. E. Van Rooij and E. N. Olson, "MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles," Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 860-872, 2012.
40. J. Y. Du, L. F. Wang, Q. Wang, and L. D. Yu, "miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells," Oncology Reports, vol. 33, no. 4, pp. 1890-1898, 2015.
41. B. Icli, P. Dorbala, and M. W. Feinberg, "An emerging role for the miR-26 family in cardiovascular disease," Trends in Cardiovascular Medicine, vol. 24, no. 6, pp. 241-248, 2014.
42. X. Y. Qi, H. Huang, B. Ordog et al., "Fibroblast inwardrectifier potassium current upregulation in profibrillatory atrial remodeling," Circulation Research, vol. 116, no. 5, pp. 836-845, 2015.
43. M. Long, X. Wan, X. La, X. Gong, and X. Cai, "miR-29c is downregulated in the ectopic endometriumandexerts its effects on endometrial cell proliferation, apoptosis and invasion by targeting c-Jun," International Journal of Molecular Medicine, pp. 1119-1125, 2015.
44. Y. Dai, D. Dai, and J. L. Mehta, "MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker," Journal of the American College of Cardiology, vol. 64, no. 20, p. 2181, 2014.
45. J. Wang, X. Guan, F. Guo et al., "miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6," Cell Death & Disease, vol. 4, no. 10, article e845, 2013.
46. C. W. Cheng, H. W. Wang, C. W. Chang et al., "MicroRNA- 30a inhibits cell migration and invasion by down regulating vimentin expression and is a potential prognostic marker in breast cancer," Breast Cancer Research and Treatment, vol. 134, no. 3, pp. 1081-1093, 2012.
47. W. Pan, Y. Zhong, C. Cheng et al., "MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy," PLoS ONE, vol. 8, no. 1, Article ID e53950, 2013.
48. G. Long, F. Wang, Q. Duan et al., "Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction," PLoS ONE, vol. 7, no. 12, Article IDe50926, 2012.
49. S. Brockway and N. J. Zeleznik-Le, "WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia," Cancer Genetics, vol. 208, no. 5, pp. 279-287, 2015.
50. D. Chacon-Cortes, R. A. Smith, R. A. Lea, P. H. Youl, and L. R. Griffiths, "Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer," Tumor Biology, 2015.
51. C. Ye, N. X. Sun, Y. Ma et al., "MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells," FEBS Letters, vol. 589, no. 6, pp. 702-709, 2015.
52. H. Liang, Z. Jiang, G. Xie, and Y. Lu, "Serum microRNA-145 as a novel biomarker in human ovarian cancer," Tumor Biology, 2015.
53. T. Han, X. P. Yi, B. Liu, M. J. Ke, and Y. X. Li, "MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9," Molecular Medicine Reports, vol. 11, no. 6, pp. 4115-4120, 2015.
54. B. Hu, J. T. Song, H. Y. Qu et al., "Mechanical stretch suppresses microRNA-145 expression by activating extracellular signalregulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype," PLoS ONE, vol. 9, no. 5, Article ID e96338, 2014.
55. M. Ohnaka, A. Marui, K. Yamahara et al., "Effect ofmicroRNA- 145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype," The Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 2, pp. 676-682.e2, 2014.
56. E. van Rooij and S. Kauppinen, "Development of microRNA therapeutics is coming of age," EMBO Molecular Medicine, vol. 6, no. 7, pp. 851-864, 2014.
57. H. L. A. Janssen, H. W. Reesink, E. J. Lawitz et al., "Treatment of HCV infection by targeting microRNA," The New England Journal of Medicine, vol. 368, no. 18, pp. 1685-1694, 2013.
58. G. Santulli, A. Wronska, K. Uryu et al., "A selective microRNAbased strategy inhibits restenosis while preserving endothelial function," The Journal of Clinical Investigation, vol. 124, no. 9, pp. 4102-4114, 2014.